Our efforts have resulted in effective degradation of BCR–ABL protein by the N-end rule pathway and efficient growth inhibition of K562 cells expressing BCR–ABL in vitro and blunted tumor growth in a K562 xenograft tumor model in vivo. Here, ABL1 is linked to neoplasm.